این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Basic and Clinical Neuroscience، جلد ۱۲، شماره ۲، صفحات ۲۳۳-۲۴۲
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
چکیده انگلیسی مقاله Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of Dadolinium (Gd)-enhanced lesions, enlarged T2 lesions, and relapses over 12 months were considered as endpoints and compared to baseline. Liver biochemical evaluations and lymphocyte count were done at baseline and in months 3, 6, and 12 of the study. Patients were also monitored for possible cardiovascular events within the first 24 h and other side effects routinely. Results: Among the patients who completed the trial, the number of Gd-enhanced and enlarged T2 lesions over 12 months significantly decreased (P=0.03 and P< 0.001, respectively). The proportion of relapse-free patients was higher compared to the onset of fingolimod administration. There were no significant alterations in the Expanded Disability Status Scale (EDSS) scores. A slight, transient increase was recorded in liver enzymes among the participants. Lymphocyte count reduced by 61% at month 1 and displayed a gradual increase until month 12. No bradycardia and macular edema were recorded. Conclusion: These findings indicate an effective first-line fingolimod therapy for the first time in Iranian patients with RRMS. The decrease in the number of new attacks and the amelioration of MRI lesions were the benefits of fingolimod therapy, suggesting that it is preferred to other medicines to treat RRMS in Iran.
کلیدواژه‌های انگلیسی مقاله Multiple sclerosis, Fingolimod, Expanded Disability Status Scale (EDSS), Magnetic Resonance Imaging (MRI), Cardiovascular events, Therapy
نویسندگان مقاله | Fatemeh Yavari
Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.


| Pardis Oliazadeh
School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.


| Meisam Radfar
Department of Biotechnology and Plant Breeding, Gorgan University of Agricultural Sciences and Natural Recourses, Golestan, Iran.


| Mohsen Foroughipour
Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.


| Karim Nikkhah
Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.


| Alireza Heidari Bakavoli
Department of Cardiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.


| Morteza Saeidi
Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
نشانی اینترنتی http://bcn.iums.ac.ir/browse.php?a_code=A-10-1681-1&slc_lang=en&sid=1
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده Clinical Neuroscience
نوع مقاله منتشر شده Original
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات